|
|
Over-expression of MiR-26b-5p inhibits HMGA1 expression and participates in epithelial-mesenchymal transformation of ovarian cancer cells |
CAO Wenhong |
Department of Obstetrics and Gynecology, Women and Children’s Hospital of Qingdao, Qingdao 266000 China |
|
|
Abstract Objective To explore the mechanism by which microRNA-26b-5p (miR-26b-5p) mediates high-mobility group A1 (HMGA1) in epithelial-mesenchymal transformation of ovarian cancer.Methods The target gene of microRNA-26b-5p was predicted. The expressions of miR-26b-5p and HMGA1 in tissues were detected by real-time reverse transcription PCR (qRT-PCR). After grouping and transfection of ovarian cancer cells, the expressions of mRNA and protein of relevant factors were detected by qRT-PCR and Western blot in the cells. Transwell invasion test was used to detect cell invasion and scratch test to detect migration ability, while qRT-PCR and Western blot were used to detect the expressions of E-cadherin and Vimentin genes related to epithelial-mesenchymal transformation in tumors.Results The expression of miR-26b-5p in ovarian cancer tissue decreased, while the expression of HMGA1 increased (All P<0.05). miR-26b-5p mimic and sh-HMGA1 groups showed decreased expressions of HMGA1 and Vimentin, increased expression of E-cadherin, and reduced cell invasion and migration (All P<0.05). Co-transfection of miR-26b-5p inhibitor and sh-HMGA1 reversed the inhibitory effect of sh-HMGA1 on epithelial-mesenchymal transformation (All P<0.05).Conclusions Over-expression of miR-26b-5p inhibits the expressions of HMGA1 and Vimentin in ovarian cancer cells, promotes E-cadherin expression, reduces cell invasion and migration, thus inhibiting epithelial-mesenchymal transformation of ovarian cancer cells.
|
Received: 25 March 2019
|
|
|
|
|
[1] |
Reid B M, Permuth J B, Sellers T A. Epidemiology of ovarian cancer: a review[J]. Cancer Bio Med, 2017, 14(1):9-32.
|
[2] |
Huo W, Zhao G, Yin J, et al. Lentiviral CRISPR/Cas9 vector mediated miR-21 gene editing inhibits the epithelial to mesenchymal transition in ovarian cancer cells[J]. J Cancer, 2017, 8(1):57.
|
[3] |
崔洪亮, 张阳德, 任 菲,等. dbDEMC2.0:人类癌症相关miRNA数据库2.0[J]. 中国现代医学杂志, 2014, 24(3):77-79.
|
[4] |
Piotrowskidaspit A S, Tien J, Nelson C M. Interstitial fluid pressure regulates collective invasion in engineered human breast tumors via Snail, vimentin, and E-cadherin[J]. Integr Biol, 2016, 8(3):319-331.
|
[5] |
Yamashita N, Tokunaga E, Inoue Y, et al. Epithelial paradox; clinical significance of co-expression of E-cadherin and vimentin in the invasion and the metastasis of breast cancer[J]. Cancer Res, 2017, 17(4):6-17.
|
[6] |
Lin J, Zhang L, Huang H, et al. MiR-26b/KPNA2 axis inhibits epithelial ovarian carcinoma proliferation and metastasis through downregulating OCT4[J]. Oncotarget, 2015, 6(27):23793-23806.
|
[7] |
李 励, 冯 浩, 刘胜楠,等. miR-26b在卵巢癌组织中的表达水平及其与预后的关系[J]. 临床和实验医学杂志, 2017, 16(17):1700-1703.
|
[8] |
张英芝. HMGA1在卵巢上皮性癌组织中的表达及临床意义[J]. 肿瘤学杂志, 2014, 20(1):51-54.
|
[9] |
Wu T, Chen W, Liu S, et al. Huaier suppresses proliferation and induces apoptosis in human pulmonary cancer cells via upregulation of miR-26b-5p[J]. Febs Lett, 2014, 588(12):2107-2114.
|
[10] |
Liu C Y, Lin H H, Tang M J, et al. Vimentin contributes to epithelial-mesenchymal transition cancer cell mechanics by mediating cytoskeletal organization and focal adhesion maturation[J]. Oncotarget, 2015, 6(18):15966-15983.
|
[11] |
Zhu G, Zhu G, Song P, et al. Role of epithelial-mesenchymal transition markers E-cadherin, N-cadherin, β-catenin and ZEB2 in laryngeal squamous cell carcinoma[J]. Oncol Lett, 2018, 15(3):3472-3481.
|
[12] |
柳培雨, 田 毅, 鲍缦夕,等. 大鼠心肌缺血-再灌注损伤miRNA-214介导电针预处理的保护作用[J]. 武警医学, 2016, 27(1):43-47.
|
[13] |
Li W, Zhang X, Ji W, et al. TGFβ1 in fibroblasts-derived exosomes promotes epithelial-mesenchymal transition of ovarian cancer cells[J]. Oncotarget, 2017, 8(56):96035-96047.
|
[14] |
Park G B, Ko H, Kim D. Sorafenib controls the epithelial-mesenchymal transition of ovarian cancer cells via EGF and the CD44-HA signaling pathway in a cell type-dependent manner[J]. Mol Med Rep, 2017, 16(2):1826-1836.
|
[1] |
. [J]. Med. J. Chin. Peop. Armed Poli. Forc., 2016, 27(2): 193-196. |
|
|
|
|